News

Filter

1 to 9 of 43 results

Positive response from European regulatory procedure supports Shire's Elvanse for ADHD

18-12-2012

Ireland headquartered Shire (LSE: SHP) yesterday announced a positive outcome from the European Decentralized…

ElvanseEuropelisdexamfetamine dimesylateNeurologicalPharmaceuticalRegulationShireTyvenseVyvanse

US Court upholds FDA’s grant of five-year market exclusivity for Shire’s ADHD drug Vyvanse

05-03-2010

The US District Court for the District of Columbia has upheld the Food and Drug Administration’s…

Genericslisdexamfetamine dimesylateNeurologicalNorth AmericaPatentsPharmaceuticalRegulationShireVyvanse

US FDA says Shire’s Vyvanse was properly granted five-year market exclusivity

26-10-2009

The US Food and Drug Administration, following a thorough administrative review of governing statutory…

GenericsGlaxoSmithKlineGSKlisdexamfetamine dimesylateNeurologicalNorth AmericaPatentsPharmaceuticalShireVyvanse

Shire sales up 20% pre-Adderall demise

01-05-2009

Specialty pharmaceuticals firm Shire has reported a 20% increase in first-quarter 2009 product sales,…

AdderallAmphetamineDextroamphetamine Mixed SaltsElapraseGlaxoSmithKlineGSKIdursulfase SolutionLialdalisdexamfetamine dimesylateMesalamineShireVyvanse

GSK/Shire Vyvanse deal fuels speculation

01-04-2009

The UK's Shire has entered a co-promotion agreement with drug major GlaxoSmithKline for Vyvanse (lisdexamfetamine…

GlaxoSmithKlineGSKlisdexamfetamine dimesylateShireVyvanse

1 to 9 of 43 results

COMPANY SPOTLIGHT

Menarini

Back to top